{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T22:57:21Z","timestamp":1791241041721,"version":"4.1.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":89,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Retin Vitr"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Faricimab is a bispecific monoclonal antibody targeting both vascular endothelial growth factor A and angiopoietin-2, approved for macular oedema secondary to retinal vein occlusion in 2023. The phase III BALATON and COMINO trials demonstrated non-inferiority to aflibercept at week 24, and several real-world cohorts have subsequently emerged. The aim of this systematic review and meta-analysis was to estimate the pooled effect of faricimab on visual acuity, treatment burden, anatomical outcomes, and safety in this indication.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials were systematically searched from inception to 1 May 2026 for studies reporting outcomes following intravitreal faricimab. Risk of bias was assessed in duplicate using the Cochrane Risk of Bias 2 tool for the randomised evidence and the Risk Of Bias In Non-randomised Studies of Interventions tool for the observational evidence, with single-arm cohorts evaluated as pre-post comparisons. The primary visual acuity outcome was pooled using random-effects meta-analysis with Hartung-Knapp-Sidik-Jonkman adjustment, stratified by treatment status, while outcomes precluded from pooling by methodological heterogeneity were synthesised narratively. Certainty of evidence was assessed using the Grading of Recommendations, Assessment, Development and Evaluation framework.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Ten studies comprising 1,620 eyes met eligibility criteria, including the BALATON and COMINO randomised controlled trials and nine non-randomised cohorts. The pooled mean change in best-corrected visual acuity at approximately 6 months was +\u200916.89 Early Treatment Diabetic Retinopathy Study letters (95% confidence interval 16.05 to 17.72) in treatment-na\u00efve eyes and +\u20098.73 letters (95% confidence interval 4.75 to 12.71) in refractory switch cohorts, with negligible between-study heterogeneity in both analyses. Narrative synthesis was consistent with treatment interval extension following initiation of or switch to faricimab, statistically significant reductions in central retinal thickness across studies, and a short-term safety profile without identified retinal vasculitis events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The synthesis is consistent with intravitreal faricimab use being associated with visual and anatomical improvement in macular oedema secondary to retinal vein occlusion, with the treatment-na\u00efve pooled estimate primarily reflecting registration trial data and the switch cohort estimate characterising refractory phenotypes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40942-026-00899-y","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T11:27:15Z","timestamp":1783596435000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness and safety of intravitreal faricimab for macular oedema secondary to retinal vein occlusion: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"12","author":[{"given":"Ali","family":"Alseneid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivam","family":"Bhindi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Saleki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diya","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"issue":"1","key":"899_CR1","doi-asserted-by":"publisher","first-page":"010427","DOI":"10.7189\/jogh.09.010427","volume":"9","author":"P Song","year":"2019","unstructured":"Song P, Xu Y, Zha M, Zhang Y, Rudan I. Global epidemiology of retinal vein occlusion: a systematic review and meta-analysis of prevalence, incidence, and risk factors. J Glob Health. 2019;9(1):010427.","journal-title":"J Glob Health"},{"issue":"2","key":"899_CR2","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.ophtha.2009.07.017","volume":"117","author":"S Rogers","year":"2010","unstructured":"Rogers S, McIntosh RL, Cheung N, Lim L, Wang JJ, Mitchell P, et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology. 2010;117(2):313\u2013e3191.","journal-title":"Ophthalmology"},{"issue":"10266","key":"899_CR3","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1016\/S0140-6736(20)31559-2","volume":"396","author":"IU Scott","year":"2020","unstructured":"Scott IU, Campochiaro PA, Newman NJ, Biousse V. Retinal vascular occlusions. Lancet. 2020;396(10266):1927\u201340.","journal-title":"Lancet"},{"issue":"11","key":"899_CR4","doi-asserted-by":"publisher","first-page":"3457","DOI":"10.3390\/jcm9113457","volume":"9","author":"H Noma","year":"2020","unstructured":"Noma H, Yasuda K, Shimura M. Cytokines and pathogenesis of central retinal vein occlusion. J Clin Med. 2020;9(11):3457.","journal-title":"J Clin Med"},{"issue":"4","key":"899_CR5","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1038\/mt.2008.10","volume":"16","author":"PA Campochiaro","year":"2008","unstructured":"Campochiaro PA, Hafiz G, Shah SM, Nguyen QD, Ying H, Do DV, et al. Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator. Mol Ther. 2008;16(4):791\u20139.","journal-title":"Mol Ther"},{"issue":"6","key":"899_CR6","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/j.ophtha.2010.02.022","volume":"117","author":"DM Brown","year":"2010","unstructured":"Brown DM, Campochiaro PA, Singh RP, Li Z, Gray S, Saroj N, et al. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary endpoint results of a phase III study. Ophthalmology. 2010;117(6):1124\u2013e11331.","journal-title":"Ophthalmology"},{"issue":"12","key":"899_CR7","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1016\/j.ophtha.2017.06.027","volume":"124","author":"R Tadayoni","year":"2017","unstructured":"Tadayoni R, Waldstein SM, Boscia F, Gerding H, Gekkieva M, Barnes E, et al. Sustained benefits of ranibizumab with or without laser in branch retinal vein occlusion: 24-month results of the BRIGHTER study. Ophthalmology. 2017;124(12):1778\u201387.","journal-title":"Ophthalmology"},{"issue":"2","key":"899_CR8","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.ophtha.2015.09.035","volume":"123","author":"WL Clark","year":"2016","unstructured":"Clark WL, Boyer DS, Heier JS, Haller JA, Vitti R, Kazmi H, et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: 52-week results of the VIBRANT study. Ophthalmology. 2016;123(2):330\u20136.","journal-title":"Ophthalmology"},{"issue":"7","key":"899_CR9","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1016\/j.ophtha.2014.01.027","volume":"121","author":"JS Heier","year":"2014","unstructured":"Heier JS, Clark WL, Boyer DS, Brown DM, Vitti R, Berliner AJ, et al. Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study. Ophthalmology. 2014;121(7):1414\u2013e14201.","journal-title":"Ophthalmology"},{"issue":"12","key":"899_CR10","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1136\/bjophthalmol-2020-317337","volume":"105","author":"TA Ciulla","year":"2021","unstructured":"Ciulla TA, Pollack JS, Williams DF. Visual acuity outcomes and anti-VEGF therapy intensity in macular oedema due to retinal vein occlusion: a real-world analysis of 15 613 patient eyes. Br J Ophthalmol. 2021;105(12):1696\u2013704.","journal-title":"Br J Ophthalmol"},{"issue":"7","key":"899_CR11","first-page":"1304","volume":"61","author":"RB Bhisitkul","year":"2020","unstructured":"Bhisitkul RB, Blotner S, Steffen V, Haskova Z. Clinical trial versus real-world outcomes with anti-VEGF therapy for central retinal vein occlusion. Invest Ophthalmol Vis Sci. 2020;61(7):1304.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"899_CR12","doi-asserted-by":"publisher","first-page":"e001188","DOI":"10.1136\/bmjophth-2022-001188","volume":"7","author":"R Wang","year":"2022","unstructured":"Wang R, McClard CK, Laswell S, Mamoudzadeh R, Salabati M, Ammar M, et al. Quantifying burden of intravitreal injections: questionnaire assessment of life impact of treatment by intravitreal injections (QUALTII). BMJ Open Ophthalmol. 2022;7(1):e001188.","journal-title":"BMJ Open Ophthalmol"},{"issue":"1","key":"899_CR13","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/s12886-019-1208-9","volume":"19","author":"V Daien","year":"2019","unstructured":"Daien V, Eldem BM, Talks JS, Korobelnik JF, Mitchell P, Finger RP, et al. Real-world data in retinal diseases treated with anti-vascular endothelial growth factor (anti-VEGF) therapy: a systematic approach to identify and characterize data sources. BMC Ophthalmol. 2019;19(1):206.","journal-title":"BMC Ophthalmol"},{"issue":"7","key":"899_CR14","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1016\/j.ophtha.2015.04.006","volume":"122","author":"PA Campochiaro","year":"2015","unstructured":"Campochiaro PA, Hafiz G, Mir TA, Scott AW, Solomon S, Zimmer-Galler I, et al. Scatter photocoagulation does not reduce macular edema or treatment burden in patients with retinal vein occlusion: the RELATE trial. Ophthalmology. 2015;122(7):1426\u201337.","journal-title":"Ophthalmology"},{"issue":"10326","key":"899_CR15","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","volume":"399","author":"JS Heier","year":"2022","unstructured":"Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022;399(10326):729\u201340.","journal-title":"Lancet"},{"issue":"11","key":"899_CR16","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.15252\/emmm.201505889","volume":"8","author":"JT Regula","year":"2016","unstructured":"Regula JT, von Lundh P, Foxton R, Krohne TU, Sahni J, Bright H, et al. Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases. EMBO Mol Med. 2016;8(11):1265\u201388.","journal-title":"EMBO Mol Med"},{"issue":"5","key":"899_CR17","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1038\/s41433-020-01377-x","volume":"35","author":"AM Joussen","year":"2021","unstructured":"Joussen AM, Ricci F, Paris LP, Korn C, Quezada-Ruiz C, Zarbin M. Angiopoietin\/Tie2 signalling and its role in retinal and choroidal vascular diseases: a review of preclinical data. Eye (Lond). 2021;35(5):1305\u201316.","journal-title":"Eye (Lond)"},{"issue":"8","key":"899_CR18","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/j.ophtha.2024.01.029","volume":"131","author":"R Tadayoni","year":"2024","unstructured":"Tadayoni R, Paris LP, Danzig CJ, Abreu F, Khanani AM, Brittain C, et al. Efficacy and safety of faricimab for macular edema due to retinal vein occlusion: 24-week results from the BALATON and COMINO trials. Ophthalmology. 2024;131(8):950\u201360.","journal-title":"Ophthalmology"},{"issue":"9","key":"899_CR19","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/j.oret.2025.03.005","volume":"9","author":"CJ Danzig","year":"2025","unstructured":"Danzig CJ, Dinah C, Ghanchi F, Hattenbach LO, Khanani AM, Lai TYY, et al. Faricimab treat-and-extend dosing for macular edema due to retinal vein occlusion: 72-week results from the BALATON and COMINO trials. Ophthalmol Retina. 2025;9(9):848\u201359.","journal-title":"Ophthalmol Retina"},{"key":"899_CR20","unstructured":"Chugai Pharmaceutical Co. Ltd. Faricimab approval for retinal vein occlusion in Japan. Chugai News Release. Published 26 March 2024. Available from: https:\/\/www.chugai-pharm.co.jp\/english\/news\/detail\/20240326160000_1054.html."},{"key":"899_CR21","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s40942-026-00804-7","volume":"12","author":"L Wu","year":"2026","unstructured":"Wu L, Rojas S, Rao X, Politis M, Roca JA, Nehemy M, et al. Early Latin American experience with faricimab for retinal diseases: FARI-LATAM study for the Pan-American Collaborative Retina Study (PACORES) group. Int J Retina Vitreous. 2026;12:48.","journal-title":"Int J Retina Vitreous"},{"key":"899_CR22","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"key":"899_CR23","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/2046-4053-1-2","volume":"1","author":"A Booth","year":"2012","unstructured":"Booth A, Clarke M, Dooley G, Ghersi D, Moher D, Petticrew M, Stewart L. The nuts and bolts of PROSPERO: an international prospective register of systematic reviews. Syst Rev. 2012;1:2.","journal-title":"Syst Rev"},{"key":"899_CR24","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.","journal-title":"BMJ"},{"key":"899_CR25","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, Savovi\u0107 J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919.","journal-title":"BMJ"},{"issue":"1","key":"899_CR26","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/jrsm.1411","volume":"12","author":"LA McGuinness","year":"2021","unstructured":"McGuinness LA, Higgins JPT. Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments. Res Synth Methods. 2021;12(1):55\u201361.","journal-title":"Res Synth Methods"},{"issue":"2","key":"899_CR27","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/S0002-9394(02)01825-1","volume":"135","author":"RW Beck","year":"2003","unstructured":"Beck RW, Moke PS, Turpin AH, Ferris FL 3rd, SanGiovanni JP, Johnson CA, et al. A computerized method of visual acuity testing: adaptation of the early treatment of diabetic retinopathy study testing protocol. Am J Ophthalmol. 2003;135(2):194\u2013205.","journal-title":"Am J Ophthalmol"},{"key":"899_CR28","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1471-2288-14-135","volume":"14","author":"X Wan","year":"2014","unstructured":"Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range. BMC Med Res Methodol. 2014;14:135.","journal-title":"BMC Med Res Methodol"},{"key":"899_CR29","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. Cochrane Handbook for Systematic Reviews of Interventions. Version 6.5 (updated August 2024). Cochrane; 2024. Available from https:\/\/www.training.cochrane.org\/handbook."},{"issue":"3","key":"899_CR30","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177\u201388.","journal-title":"Control Clin Trials"},{"key":"899_CR31","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/1471-2288-14-25","volume":"14","author":"J IntHout","year":"2014","unstructured":"IntHout J, Ioannidis JPA, Borm GF. The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method. BMC Med Res Methodol. 2014;14:25.","journal-title":"BMC Med Res Methodol"},{"key":"899_CR32","doi-asserted-by":"publisher","first-page":"e64016","DOI":"10.2196\/64016","volume":"27","author":"JT Fekete","year":"2025","unstructured":"Fekete JT, Gy\u0151rffy B. MetaAnalysisOnline.com: web-based tool for the rapid meta-analysis of clinical and epidemiological studies. J Med Internet Res. 2025;27:e64016.","journal-title":"J Med Internet Res"},{"issue":"7650","key":"899_CR33","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Sch\u00fcnemann HJ, GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924\u20136.","journal-title":"BMJ"},{"issue":"20","key":"899_CR34","doi-asserted-by":"publisher","first-page":"7197","DOI":"10.3390\/jcm14207197","volume":"14","author":"M Hafner","year":"2025","unstructured":"Hafner M, Herold TR, Kufner A, Eckardt F, Asani B, Priglinger SG, Schiefelbein J. Extended real-world efficacy of faricimab in therapy-resistant macular edema due to retinal vein occlusion: 9-month follow-up results. J Clin Med. 2025;14(20):7197.","journal-title":"J Clin Med"},{"issue":"6","key":"899_CR35","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1007\/s10384-025-01237-9","volume":"69","author":"T Hikichi","year":"2025","unstructured":"Hikichi T, Kurabe H, Notoya A, Oguro Y, Hirano M, Doi Y. Short-term outcomes of switching to faricimab for macular edema secondary to retinal vein occlusion. Jpn J Ophthalmol. 2025;69(6):918\u201325.","journal-title":"Jpn J Ophthalmol"},{"issue":"2","key":"899_CR36","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s10384-025-01254-8","volume":"70","author":"T Hikichi","year":"2026","unstructured":"Hikichi T, Kurabe H, Notoya A, Oguro Y, Hirano M, Doi Y. Six-month comparative outcomes of aflibercept and faricimab in treatment-na\u00efve macular edema secondary to branch retinal vein occlusion. Jpn J Ophthalmol. 2026;70(2):117\u201322.","journal-title":"Jpn J Ophthalmol"},{"key":"899_CR37","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s40942-025-00703-3","volume":"11","author":"T Hirakata","year":"2025","unstructured":"Hirakata T, Toride A, Ashikaga K, Nakagawa T, Hara F, Nochi Y, et al. Short-term real-world effectiveness of faricimab on macular edema due to retinal vein occlusion. Int J Retina Vitreous. 2025;11:79.","journal-title":"Int J Retina Vitreous"},{"key":"899_CR38","doi-asserted-by":"publisher","first-page":"3669","DOI":"10.2147\/OPTH.S549896","volume":"19","author":"S Inokuchi","year":"2025","unstructured":"Inokuchi S, Mizuki Y, Kamata A, Onishi J, Hayashi T, Mizuki N. Real-world efficacy of intravitreal faricimab for macular edema secondary to retinal vein occlusion: short-term outcomes and optical coherence tomography biomarker analysis. Clin Ophthalmol. 2025;19:3669\u201379.","journal-title":"Clin Ophthalmol"},{"key":"899_CR39","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s12886-026-04695-y","volume":"26","author":"A Kilani","year":"2026","unstructured":"Kilani A, Assaf A, Vogt D, Vounotrypidis E, Parlak M, Jochem C, Wolf A. Short-term real-world outcomes of switching to faricimab in anti-VEGF-refractory retinal vein occlusion: a prospective study. BMC Ophthalmol. 2026;26:114.","journal-title":"BMC Ophthalmol"},{"key":"899_CR40","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s10792-025-03836-4","volume":"45","author":"Y Sun","year":"2025","unstructured":"Sun Y, Zhao M, Miao H, Qi H. Real-life short-term experience of switching from other anti-VEGF therapy to faricimab in patients with refractory macular edema secondary to retinal vein occlusion in China. Int Ophthalmol. 2025;45:463.","journal-title":"Int Ophthalmol"},{"key":"899_CR41","doi-asserted-by":"crossref","unstructured":"Wolfrum P, B\u00f6hm EW, Welzel AM, K\u00f6nig S, Lorenz K, Stoffelns B, Korb CA. Short-term clinical outcomes after switching to faricimab in patients affected by macular edema secondary to retinal vein occlusion: a real-world study. Eur J Ophthalmol. 2026:11206721261444780.","DOI":"10.1177\/11206721261444780"},{"issue":"17","key":"899_CR42","doi-asserted-by":"publisher","first-page":"3574","DOI":"10.1038\/s41433-023-02553-5","volume":"37","author":"AM Khanani","year":"2023","unstructured":"Khanani AM, Aziz AA, Khan H, Gupta A, Mojumder O, Saulebayeva A, et al. The real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: the TRUCKEE study\u2009\u2013\u20096 month results. Eye (Lond). 2023;37(17):3574\u201381.","journal-title":"Eye (Lond)"},{"issue":"8","key":"899_CR43","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.ophtha.2024.02.014","volume":"131","author":"AM Khanani","year":"2024","unstructured":"Khanani AM, Kotecha A, Chang A, Chen SJ, Chen Y, Guymer R, et al. TENAYA and LUCERNE: two-year results from the phase 3 neovascular age-related macular degeneration trials of faricimab with treat-and-extend dosing in year 2. Ophthalmology. 2024;131(8):914\u201326.","journal-title":"Ophthalmology"},{"key":"899_CR44","doi-asserted-by":"publisher","first-page":"3350","DOI":"10.1038\/s41433-025-04059-8","volume":"39","author":"T Peto","year":"2025","unstructured":"Peto T, Pearce I, Talks J, de Salvo G, Patel PJ, de Silva SR, et al. Real-world treatment patterns and visual outcomes of faricimab in patients with diabetic macular oedema in the UK at 12 months: the FARWIDE-DMO study. Eye (Lond). 2025;39:3350\u20138.","journal-title":"Eye (Lond)"}],"container-title":["International Journal of Retina and Vitreous"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40942-026-00899-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-026-00899-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-026-00899-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T22:34:50Z","timestamp":1791239690000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40942-026-00899-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,9]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["899"],"URL":"https:\/\/doi.org\/10.1186\/s40942-026-00899-y","relation":{},"ISSN":["2056-9920"],"issn-type":[{"value":"2056-9920","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,9]]},"assertion":[{"value":"4 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"134"}}